The role of apelin in the assessment of response to chemotherapy and prognosis in stage 4 nonsmall cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorErmin, Sinem
dc.contributor.authorCok, Gursel
dc.contributor.authorVeral, Ali
dc.contributor.authorKose, Timur
dc.date.accessioned2019-10-27T22:57:44Z
dc.date.available2019-10-27T22:57:44Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: Prediction of response to chemotherapy and prognosis bears clinical significance in patients with lung cancer. The aim of the study was to examine the association between apelin expression in tumor tissues and overall survival, progression-free survival, chemoresistance, and treatment response in stage 4 nonsmall cell lung cancer (NSCLC) patients undergoing chemotherapy. Materials and methods: A total of 81 patients who received chemotherapy due to a biopsy-documented diagnosis of NSCLC between 2004 and 2011 were retrospectively studied. Bronchoscopic biopsy samples were examined immunohistochemically. Results: Of the overall study population (n = 81), the mean age was 59.0 +/- 9.2 years; 83% (n = 67) were male and 17% (n = 14) were female. All patients received chemotherapy. A total of 30 patients (37%) had no apelin positivity, while 21 (30%) had 1 +, 20 (25%) had 2 +, and 10 (12%) had 3 + apelin positivity. We detected no association between apelin positivity and overall survival, 6-month survival, or 1-year survival rates (P = 0.05, 0.74, and 0.63). Patients with apelin expression as compared to those without it had shorter overall survival (P = 0.05). Conclusion: Our results suggest that apelin, an angiogenic factor, does not seem to provide significant prognostic information in this patient group.en_US
dc.identifier.doi10.3906/sag-1411-9en_US
dc.identifier.endpage1359en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.pmid27966297en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1353en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1411-9
dc.identifier.urihttps://hdl.handle.net/11454/51311
dc.identifier.volume46en_US
dc.identifier.wosWOS:000389053000013en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNonsmall cell lung canceren_US
dc.subjectapelinen_US
dc.subjectprognosisen_US
dc.titleThe role of apelin in the assessment of response to chemotherapy and prognosis in stage 4 nonsmall cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu